Moderate

Hypertensive heart disease & left ventricular hypertrophy

End-organ cardiac damage · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic hypertension causes left ventricular hypertrophy, diastolic dysfunction and ultimately heart failure, atrial fibrillation and increased sudden-death risk. Regression of hypertrophy with blood-pressure control improves outcomes.

Red flags

  • New heart failure symptoms
  • Syncope (consider arrhythmia or outflow obstruction)
  • Atrial fibrillation with rapid rates
  • Chest pain suggesting ischaemia
  • Very high LV mass with features suggesting an alternative cardiomyopathy

Assessment

Differential diagnosis

  • Hypertensive LVH
  • Hypertrophic cardiomyopathy
  • Aortic stenosis LVH
  • Infiltrative cardiomyopathy (amyloid)
  • Athlete's heart
  • HFpEF of other cause

Investigations

  • ECG (LVH voltage criteria, strain pattern)
  • Echocardiogram (wall thickness, LV mass, diastolic function)
  • Cardiac MRI to clarify aetiology if uncertain
  • Ambulatory BP monitoring
  • Renal function and urine ACR
  • NT-proBNP if heart failure suspected

Management

  • Confirm LVH on echo/ECG and relate it to blood-pressure history
  • Exclude mimics such as HCM, amyloid and aortic stenosis
  • Assess diastolic function and screen for heart failure with preserved EF
  • Pursue strict blood-pressure control to promote hypertrophy regression
  • Favour RAAS blockade (ACEi/ARB), which best regresses LV mass
  • Add a calcium blocker or thiazide-like diuretic to reach target
  • Screen for and manage atrial fibrillation
  • Manage HFpEF symptoms with diuretics for congestion and an SGLT2 inhibitor
  • Treat concurrent coronary disease and risk factors aggressively
  • Reinforce lifestyle: salt reduction, weight loss, exercise, alcohol limits
  • Monitor LV mass regression over time
  • Arrange cardiology follow-up if heart failure or arrhythmia develops

Drugs & doses

Ramipril 2.5-10 mg PO OD (or candesartan 8-32 mg OD) — best for LVH regression
Amlodipine 5-10 mg PO OD
Indapamide 1.5-2.5 mg PO OD
Dapagliflozin 10 mg PO OD if HFpEF present
Spironolactone 25-50 mg PO OD for resistant hypertension

Disposition

GP-led hypertension optimisation with regression monitoring; cardiology referral for heart failure, arrhythmia or diagnostic uncertainty.

Complications & pitfalls

  • Heart failure (preserved then reduced EF)
  • Atrial fibrillation
  • Sudden cardiac death
  • Myocardial ischaemia
  • Stroke

Exam pearls

  • ACEi/ARB therapy produces the greatest regression of LV mass for a given BP reduction
  • Regression of LVH independently improves cardiovascular outcomes
  • Distinguish hypertensive LVH from HCM and amyloid, which change management
  • LVH is a potent risk marker for AF and sudden death
  • Strain pattern on ECG reflects more advanced hypertrophic remodelling

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.